Iodixanol as a New Contrast Agent for Cyanoacrylate Embolization: A Preliminary In Vivo Swine Study - Université de technologie de Compiègne
Article Dans Une Revue Biomedicines Année : 2023

Iodixanol as a New Contrast Agent for Cyanoacrylate Embolization: A Preliminary In Vivo Swine Study

Kévin Guillen
Pierre-Olivier Comby
Alexandra Oudot
Anne-Virginie Salsac
Nicolas Falvo
  • Fonction : Auteur
  • PersonId : 1449847
Thierry Virely
  • Fonction : Auteur
  • PersonId : 1449848
Olivia Poupardin
  • Fonction : Auteur
  • PersonId : 1449849
Mélanie Guillemin
  • Fonction : Auteur
  • PersonId : 1449850
Olivier Chevallier
Romaric Loffroy

Résumé

N-butyl cyanoacrylate (NBCA) is a lipophilic, permanent embolic glue that must be opacified for fluoroscopic guidance. Empirically, lipophilic Lipiodol Ultra Fluid ® (LUF) has been added to produce a single-phase physically stable mixture. Varying the dilution ratio allows control of glue polymerization kinetics. LUF is far more costly than water-soluble iodinated contrast agents (ICAs). Our purpose was to evaluate whether a water-soluble nonionic iso-osmolar ICA could be used instead. We embolized both renal arteries of six swine using 1:3 NBCA-LUF or NBCA-iodixanol in 1:1, 1:3, and 1:7 ratios. We used both micro-computed tomography to assess the distality of glue penetration and indexed cast ratio and histology to assess distality, arterial obliteration, vesselwall damage, and renal-parenchyma necrosis. Glue-LUF produced significantly greater indexed cast ratio and renal-artery ROI values and a significantly shorter cast-to-capsule distance. The injected volume was significantly greater with 1:7 iodixanol than with the other mixtures. No significant differences were found for histological evidence of artery obliteration, vessel-wall damage, or renal-parenchyma necrosis. This is the first study dealing with ICA alone as a contrast agent for cyanoacrylate embolization, compared to LUF. More research is needed to determine whether water-soluble nonionic iodinated agents can be used for human NBCA embolization given the good safety profile, availability, and low cost of ICA.

Fichier principal
Vignette du fichier
GuillenEtAl_InVivo_Biomedicines23.pdf (5.04 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04804769 , version 1 (26-11-2024)

Identifiants

Citer

Kévin Guillen, Pierre-Olivier Comby, Alexandra Oudot, Anne-Virginie Salsac, Nicolas Falvo, et al.. Iodixanol as a New Contrast Agent for Cyanoacrylate Embolization: A Preliminary In Vivo Swine Study. Biomedicines, 2023, 11 (12), pp.3177. ⟨10.3390/biomedicines11123177⟩. ⟨hal-04804769⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

More